# A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

> **NCT05604885** · PHASE2 · COMPLETED · sponsor: **SynAct Pharma Aps** · enrollment: 125 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** AP1189, 60 mg
- **DRUG:** AP1189, 80 mg
- **DRUG:** AP1189, 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05604885
- **Lead sponsor:** SynAct Pharma Aps
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-30
- **Primary completion:** 2023-08-28
- **Final completion:** 2023-08-28
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2024-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05604885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05604885, "A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05604885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*